ClinicalTrials.gg
Not yet recruitingNCT07892599ABPS-EAR-HOLEPUpdated Oct 23, 2026

Anterior Bridge-Preserving Versus Conventional Early Apical Release During Holmium Laser Enucleation of the Prostate

An interventional study of Anterior Bridge-Preserving Semicircular Early Apical Release (ABP-S-EAR) and Conventional Early Apical Release (EAR) in Benign Prostatic Hyperplasia, Benign Prostatic Obstruction and Stress Urinary Incontinence, sponsored by Ahmed Ebrahim Zahran. Not yet recruiting. Open to male participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Ahmed Ebrahim Zahran · Not applicable, Interventional, and Treatment

Updated Oct 23, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
45 Years to 80 Years
Sex
Male
01

Study summary

Holmium laser enucleation of the prostate (HoLEP) is an effective operation for men with urinary obstruction caused by a benign enlarged prostate. Some men leak urine for a period after the operation. Early apical release is a surgical step that frees the tip (apex) of the prostate at the start of the operation to reduce stretch on the urinary sphincter. The conventional technique cuts all the way around the apex, including the front (anterior) tissue next to the sphincter.

This randomized trial compares a modified technique, Anterior Bridge-Preserving Semicircular Early Apical Release (ABP-S-EAR), with conventional early apical release during HoLEP. ABP-S-EAR leaves the front tissue bridge between the 11 and 1 o'clock positions intact. Men aged 45 to 80 years scheduled for HoLEP at Benha University Hospital, Egypt, will be randomly assigned to one technique. The main question is whether ABP-S-EAR improves urinary continence 1 month after surgery. The trial also compares continence at 3, 6, and 12 months, operative time, bleeding, catheter time, hospital stay, urinary symptoms, urine flow, and complications.

Read the detailed description

Background. Transient stress urinary incontinence remains a common problem after HoLEP. Conventional early apical release (EAR) limits sphincter traction but uses a circumferential apical incision that divides the anterior peri-sphincteric tissue. The external urethral sphincter has anterior, lateral, and peri-prostatic relationships, which supports preserving an anterior tissue bridge during apical release.

Objective. To test whether Anterior Bridge-Preserving Semicircular Early Apical Release (ABP-S-EAR), which preserves the 11 to 1 o'clock anterior apical tissue bridge, improves early urinary continence compared with conventional EAR during HoLEP, without loss of surgical efficacy or safety.

Design. Prospective, randomized, controlled, parallel-group, single-center trial at the Urology Department, Benha University Hospital, Egypt. Recruitment of consecutive eligible men starts November 2026 and continues until the required sample size is reached.

Randomization and masking. Participants are randomized 1:1 using a computer-generated sequence with permuted blocks prepared before study start. Allocation is concealed in sequentially numbered, opaque, sealed envelopes prepared by an independent coordinator not involved in recruitment or outcome assessment. The envelope is opened in the operating room after induction of anesthesia and immediately before cystoscopy. The surgeon cannot be masked. Participants and independent outcome assessors (follow-up interviews, functional scoring, pad-weight testing) are masked to allocation.

Preoperative assessment. History, IPSS, IPSS-QoL (question 8), baseline continence status (daily pad count, leak history), PSA, complete blood count, serum creatinine, urinalysis (urine culture when indicated), uroflowmetry (Qmax), post-void residual by transabdominal ultrasound, and prostate volume and adenoma configuration by transrectal or transabdominal ultrasound.

Surgery. Spinal or general anesthesia, lithotomy position. Apical and bladder neck incisions are made with a bipolar Collins knife through a continuous-flow 26 Fr resectoscope (120 W cutting, 80 W coagulation). The bipolar working element is then exchanged for a laser working element in the same sheath, and enucleation is performed with a high-power holmium:YAG laser through a 550 µm end-firing fiber at 2.0 J and 40 Hz (80 W), with hemostasis at 1.0 J and 30 Hz. Irrigation height 60 cm H2O for enucleation and 80 to 100 cm H2O for morcellation. Energy settings, irrigation, and instruments are identical in both arms. All operations are performed by one experienced endourologist.

ABP-S-EAR arm. After cystoscopic inspection, a semicircular mucosal incision is made on the right from 6 o'clock (just proximal to the verumontanum) along the lateral mucosal groove to 11 o'clock, and on the left from 6 o'clock to 1 o'clock. The anterior apical tissue bridge between 11 and 1 o'clock is left intact. Dissection at the 11 and 1 o'clock limits uses the blunt tip of the resectoscope sheath without electrocautery, to avoid thermal injury to the anterior rhabdosphincter. Paired longitudinal incisions are made from the bladder neck at 11 and 1 o'clock down to the surgical capsule and joined to the apical incisions. The capsular plane is entered at the lateral apical releases and the lobes are mobilized retrogradely toward the bladder neck, leaving the bridge undisturbed. The lobes are detached at the bladder neck, pushed into the bladder, and removed with an intravesical mechanical morcellator. If a safe capsular plane cannot be developed, conversion to conventional EAR is allowed and the anatomical reason is recorded.

Conventional EAR arm. After cystoscopic inspection, a continuous circumferential mucosal incision is made with the same bipolar Collins knife along the proximal border of the external sphincter, through the 12 o'clock position, completely dividing the anterior mucosal bridge. Retrograde holmium laser enucleation follows by the standard institutional technique, then intravesical morcellation.

Postoperative care and follow-up. 22 Fr three-way Foley catheter with continuous saline irrigation, stopped when the effluent is clear. Trial without catheter per institutional protocol (usually postoperative day 1 or 2). Visits at 1, 3, 6, and 12 months. A standardized 1-hour pad test and questionnaires are done at 1 month. Qmax, PVR, IPSS, IPSS-QoL, pad use, and adverse events are recorded at every visit.

Outcomes. Primary: objective continence at 1 month (zero pads, no urge incontinence, 1-hour pad test weight gain of 1 g or less). Secondary: continence at 3, 6, and 12 months; operative, apical release, enucleation, and morcellation times; enucleation efficiency; hemoglobin decline; transfusion; catheter duration; hospital stay; changes in IPSS, IPSS-QoL, Qmax, and PVR to 12 months; bridge integrity; conversion rate; Clavien-Dindo complications.

Sample size. In a randomized trial of veil-sparing versus standard HoLEP, 23.1% of standard-arm patients had a positive 1-hour pad test at 1 month (continence 76.9%). An absolute increase of 15 percentage points (76.9% to 92%) is considered the minimum clinically important difference. With a two-sided chi-square test with continuity correction, alpha 0.05, and 80% power, 103 patients per arm are required; with 10% loss to follow-up, 115 per arm (230 in total).

Statistical analysis. SPSS (IBM). Normality by Shapiro-Wilk test and visual inspection. Continuous data as mean and SD or median and range; compared by independent t-test or Mann-Whitney U test. Categorical data as number and percentage; compared by chi-square or Fisher's exact test. The primary outcome is reported as proportions with the absolute difference and 95% confidence interval. Primary analysis by intention to treat (including conversions to conventional EAR), with a per-protocol sensitivity analysis. Two-sided tests, P \< 0.05 significant.

Ethics. Approval by the Research Ethics Committee, Faculty of Medicine, Benha University. Written informed consent from all participants.

02

Conditions studied

  • Benign Prostatic Hyperplasia
  • Benign Prostatic Obstruction
  • Stress Urinary Incontinence
  • Lower Urinary Tract Symptoms (LUTS) in Men With Benign Prostatic Hyperplasia (BPH)
03

In context

Prostatic Hyperplasia

803 studies on the registry are indexed under Prostatic Hyperplasia; 174 are open to participants now.

This study's planned enrollment of 230 is above the median of 96 across 610 interventional studies indexed under Prostatic Hyperplasia.

Browse Prostatic Hyperplasia studies →

Lead sponsor

This is the only study on the registry with Ahmed Ebrahim Zahran as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men aged 45 to 80 years.
  • Documented symptomatic benign prostatic obstruction (BPO) refractory to medical therapy or with BPO-related complications, with a clinical indication for endoscopic enucleation of the prostate.
  • Able to understand the study procedures and give written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Neurogenic bladder dysfunction or major neurological disorder known to impair lower urinary tract function or continence.
  • Previous prostate, bladder neck, or urethral surgery that substantially alters apical anatomy.
  • Urethral stricture or bladder neck sclerosis requiring concurrent intervention.
  • Untreated active urinary tract infection.
  • Known or histologically confirmed prostate cancer requiring active oncologic therapy.
  • Severe medical condition or any investigator-defined concern that precludes safe anesthesia, surgery, or valid outcome assessment.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
230 participants (estimated)

Study arms

  • Experimental
    ABP-S-EAR HoLEP

    Holmium laser enucleation of the prostate with Anterior Bridge-Preserving Semicircular Early Apical Release. Semicircular apical mucosal incisions run from 6 o'clock to 11 o'clock (right) and to 1 o'clock (left). The anterior apical tissue bridge between 11 and 1 o'clock is left intact. Retrograde enucleation and intravesical morcellation follow.

    Procedure: Anterior Bridge-Preserving Semicircular Early Apical Release (ABP-S-EAR)

  • Active comparator
    Conventional EAR HoLEP

    Holmium laser enucleation of the prostate with conventional early apical release. A continuous circumferential apical mucosal incision through the 12 o'clock position divides the anterior mucosal bridge. Retrograde enucleation and intravesical morcellation follow.

    Procedure: Conventional Early Apical Release (EAR)

Interventions

  • ProcedureAnterior Bridge-Preserving Semicircular Early Apical Release (ABP-S-EAR)

    Bipolar Collins knife via 26 Fr continuous-flow resectoscope (120 W cut, 80 W coagulation) for apical and bladder neck incisions. Right incision from 6 o'clock proximal to the verumontanum to 11 o'clock; left from 6 to 1 o'clock. The 11 to 1 o'clock anterior bridge is preserved; dissection at its limits uses the blunt sheath tip without electrocautery. Paired longitudinal incisions from the bladder neck at 11 and 1 o'clock join the apical incisions. Retrograde holmium laser enucleation (550 µm fiber, 2.0 J, 40 Hz) leaves the bridge undisturbed, then mechanical morcellation. Conversion to conventional EAR is allowed if a safe capsular plane cannot be developed.

    Also known as: ABP-S-EAR, semicircular early apical release

  • ProcedureConventional Early Apical Release (EAR)

    Same bipolar Collins knife, resectoscope, laser and energy settings, and irrigation as the experimental arm. Continuous circumferential mucosal incision along the proximal border of the external sphincter, through 12 o'clock, completely dividing the anterior mucosal bridge. Retrograde holmium laser enucleation by the standard institutional technique, then intravesical morcellation.

    Also known as: Conventional EAR; circumferential early apical release

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With Objective Urinary Continence at 1 Month

    Continence defined as zero pad use with no urge incontinence, confirmed by a standardized 1-hour pad test with pad weight gain of 1 g or less. Assessed by a masked outcome assessor

    Time frame: 1 month after surgery

Secondary outcomes

  1. Proportion of Participants With Urinary Continence at 3, 6, and 12 Months

    Continence defined as zero pad use with no urge incontinence, based on patient report and daily pad count

    Time frame: 3, 6, and 12 months after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — De-identified individual participant data underlying the published results will be shared on reasonable request.

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07892599
Lead sponsor
Ahmed Ebrahim Zahran
Responsible party
Ahmed Ebrahim Zahran (Lecturer of Urology, Benha University) — Sponsor-investigator
First posted
Oct 23, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
May 30, 2028 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Oct 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion